HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Badger Reformulates Sunscreens To Meet Consumer Demand For Nano-Free

This article was originally published in The Rose Sheet

Executive Summary

Amid activist group and consumer concerns about the safety of nanoparticles in sunscreens, W.S. Badger Company has reformulated its sunscreen lineup with non-nano zinc oxide while maintaining product efficacy, the firm says.

You may also be interested in...



FDA Takes “Property”-Based Approach To Nanotech, Raises Roof To 1 Micron

In its newly released guidance to industry, FDA indicates that “agglomerates and aggregates” of materials that exceed the oft-cited ceiling of 100 nanometers may still warrant consideration as nanotechnology based on their “properties,” a position that could impact the cosmetics sector.

FDA Takes “Property”-Based Approach To Nanotech, Raises Roof To 1 Micron

In its newly released guidance to industry, FDA indicates that “agglomerates and aggregates” of materials that exceed the oft-cited ceiling of 100 nanometers may still warrant consideration as nanotechnology based on their “properties,” a position that could impact the cosmetics sector.

EWG’s Sunscreen Recommendations Up From 2010, But Health Concerns Remain

With FDA’s final sunscreen monograph reportedly around the corner, a greater percentage of sunscreens garnered the Environmental Working Group’s approval this year than in past market surveys, but the group still has concerns about sunscreen regulation and ingredient safety.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS017554

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel